These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39287944)

  • 1. Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.
    Soon YY; Marschner IC; Schou M; Hofman MS; Emmett L; Davis ID; Stockler MR; Martin AJ
    JAMA Netw Open; 2024 Sep; 7(9):e2433863. PubMed ID: 39287944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
    Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival with [
    Hofman MS; Emmett L; Sandhu S; Iravani A; Buteau JP; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; Stockler MR; Williams SG; Martin AJ; Davis ID;
    Lancet Oncol; 2024 Jan; 25(1):99-107. PubMed ID: 38043558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
    Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS;
    Lancet Oncol; 2022 Nov; 23(11):1389-1397. PubMed ID: 36261050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
    Flippot R; Telli T; Velev M; Fléchon A; De Vries-Brilland M; Turpin L; Bergman A; Turco F; Mahammedi H; Fendler WP; Giraudet AL; Josset Q; Montravers F; Vogel W; Gillessen S; Berardi Vilei S; Herrmann K; Kryza D; Paone G; Hadaschik B; Merlin C; Dufour PA; Bernard-Tessier A; Naoun N; Patrikidou A; Garcia C; Foulon S; Pagès A; Fizazi K
    Eur Urol Oncol; 2024 Oct; 7(5):1132-1140. PubMed ID: 38664139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TheraP: a randomized phase 2 trial of
    Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
    BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Morris MJ; Castellano D; Herrmann K; de Bono JS; Shore ND; Chi KN; Crosby M; Piulats JM; Fléchon A; Wei XX; Mahammedi H; Roubaud G; Študentová H; Nagarajah J; Mellado B; Montesa-Pino Á; Kpamegan E; Ghebremariam S; Kreisl TN; Wilke C; Lehnhoff K; Sartor O; Fizazi K;
    Lancet; 2024 Sep; 404(10459):1227-1239. PubMed ID: 39293462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and pain outcomes with [
    Fizazi K; Herrmann K; Krause BJ; Rahbar K; Chi KN; Morris MJ; Sartor O; Tagawa ST; Kendi AT; Vogelzang N; Calais J; Nagarajah J; Wei XX; Koshkin VS; Beauregard JM; Chang B; Ghouse R; DeSilvio M; Messmann RA; de Bono J
    Lancet Oncol; 2023 Jun; 24(6):597-610. PubMed ID: 37269841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [
    Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
    Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [
    Gafita A; Martin AJ; Emmett L; Eiber M; Iravani A; Fendler WP; Buteau J; Sandhu S; Azad AA; Herrmann K; Stockler MR; Davis ID; Hofman MS
    Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38584037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Sartor O; de Bono J; Chi KN; Fizazi K; Herrmann K; Rahbar K; Tagawa ST; Nordquist LT; Vaishampayan N; El-Haddad G; Park CH; Beer TM; Armour A; Pérez-Contreras WJ; DeSilvio M; Kpamegan E; Gericke G; Messmann RA; Morris MJ; Krause BJ;
    N Engl J Med; 2021 Sep; 385(12):1091-1103. PubMed ID: 34161051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy.
    Michalski K; Kosmala A; Werner RA; Serfling SE; Seitz AK; Lapa C; Buck AK; Hartrampf PE
    Ann Nucl Med; 2024 Feb; 38(2):87-95. PubMed ID: 37891376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Michael S. Hofman, Louise Emmett, Shahneen Sandhu, et al. Overall Survival with [
    Xu J; Ding L; Yang B
    Eur Urol Oncol; 2024 Oct; 7(5):1150-1151. PubMed ID: 38378399
    [No Abstract]   [Full Text] [Related]  

  • 15. Combined
    Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
    Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
    Fallah J; Agrawal S; Gittleman H; Fiero MH; Subramaniam S; John C; Chen W; Ricks TK; Niu G; Fotenos A; Wang M; Chiang K; Pierce WF; Suzman DL; Tang S; Pazdur R; Amiri-Kordestani L; Ibrahim A; Kluetz PG
    Clin Cancer Res; 2023 May; 29(9):1651-1657. PubMed ID: 36469000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Outcomes and Predictive Biomarkers for
    Kafka M; Horninger A; di Santo G; Virgolini I; Neuwirt H; Unterrainer LM; Kunte SC; Deiss E; Paffenholz P; Heidenreich A; Rasul S; Einspieler H; Shariat SF; Rajwa P; Dozauer R; Tsaur I; Medlock E; Rölz N; Rausch S; la Fougère C; Trautwein N; Roesch MC; Merseburger AS; Zattoni F; Sepulcri M; Ladurner M; Bektic J; Gandaglia G; Horninger W; Heidegger I
    Eur Urol Oncol; 2024 Jun; 7(3):421-429. PubMed ID: 37604763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with
    Calais J; Gafita A; Eiber M; Armstrong WR; Gartmann J; Thin P; Nguyen K; Lok V; Gosa L; Grogan T; Esfandiari R; Allen-Auerbach M; Quon A; Bahri S; Gupta P; Gardner L; Ranganathan D; Slavik R; Dahlbom M; Herrmann K; Delpassand E; Fendler WP; Czernin J
    J Nucl Med; 2021 Oct; 62(10):1440-1446. PubMed ID: 34016732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.